胃肠道间质瘤治疗的最新进展
Recent advances in the management of gastrointestinal stromal tumors.
作者信息
Duffaud Florence, Salas Sebastien, Huynh Thanh
机构信息
Medical Oncology Unit, CHU La Timone Bvd J Moulin, 13385 Marseille cedex 5 France.
出版信息
F1000 Med Rep. 2010 May 11;2:36. doi: 10.3410/M2-36.
Abstract
This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant imatinib therapy despite approvals by the US Food and Drug Administration and the European Medicines Agency, and on a new marker for the diagnosis of GIST.
摘要
本报告主要聚焦于美国外科医师学会肿瘤学组（ACOSOG）Z9001试验中所确定的接受伊马替尼治疗的胃肠道间质瘤（GIST）复发风险的显著降低。它还关注尽管已获得美国食品药品监督管理局和欧洲药品管理局的批准，但辅助性伊马替尼治疗仍存在的诸多未知因素，以及一种用于GIST诊断的新标志物。
相似文献
1
Recent advances in the management of gastrointestinal stromal tumors.胃肠道间质瘤治疗的最新进展
F1000 Med Rep. 2010 May 11;2:36. doi: 10.3410/M2-36.
2
Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.伊马替尼辅助治疗1年对Kit阳性局限性胃肠间质瘤手术切除后的预算影响
J Manag Care Pharm. 2010 Sep;16(7):482-91. doi: 10.18553/jmcp.2010.16.7.482.
3
New fronts in the adjuvant treatment of GIST.GIST 辅助治疗的新领域。
Cancer Chemother Pharmacol. 2013 Oct;72(4):715-23. doi: 10.1007/s00280-013-2248-0. Epub 2013 Aug 11.
4
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.接受伊马替尼辅助治疗的胃肠道间质瘤患者复发的危险因素。
Cancer. 2014 Aug 1;120(15):2325-33. doi: 10.1002/cncr.28669. Epub 2014 Apr 15.
5
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.切除原发性胃肠道间质瘤（GIST）后的辅助治疗与长期预后的病理和分子特征相关：ACOSOG Z9001 试验。
J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17.
6
Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.辅助和新辅助伊马替尼治疗：在胃肠道间质瘤治疗中的当前作用。
Int J Cancer. 2011 Dec 1;129(11):2533-42. doi: 10.1002/ijc.26234.
7
Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.伊马替尼：作为胃肠间质瘤的辅助治疗药物。
Drugs. 2010 Oct 22;70(15):1963-72. doi: 10.2165/11205000-000000000-00000.
8
Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal.伊马替尼是欧洲用于胃肠道间质瘤切除术后有显著复发风险的成年患者的首个也是唯一治疗药物。
Clin Exp Gastroenterol. 2010;3:41-7. doi: 10.2147/ceg.s7068. Epub 2010 May 12.
9
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.局部、高危、原发性胃肠道间质瘤辅助甲磺酸伊马替尼的长期结果：ACOSOG Z9000（联盟）分组 2 期试验。
Ann Surg. 2013 Sep;258(3):422-9. doi: 10.1097/SLA.0b013e3182a15eb7.
10
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.原发性胃肠道间质瘤的显微镜下阳性切缘：风险因素和肿瘤复发分析。
J Am Coll Surg. 2012 Jul;215(1):53-9; discussion 59-60. doi: 10.1016/j.jamcollsurg.2012.05.008.
引用本文的文献
1
Behavior of advanced gastrointestinal stromal tumor in a patient with von-Recklinghausen disease: Case report.1例冯·雷克林霍增氏病患者的晚期胃肠道间质瘤表现：病例报告
World J Clin Oncol. 2013 Aug 10;4(3):70-4. doi: 10.5306/wjco.v4.i3.70.
2
Advances in adjuvant therapy of gastrointestinal stromal tumors.胃肠道间质瘤辅助治疗的进展。
Curr Oncol Rep. 2012 Aug;14(4):327-32. doi: 10.1007/s11912-012-0241-0.
本文引用的文献
1
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.比较两种剂量伊马替尼治疗不可切除或转移性胃肠道间质瘤的疗效：一项纳入 1640 例患者的荟萃分析。
J Clin Oncol. 2010 Mar 1;28(7):1247-53. doi: 10.1200/JCO.2009.24.2099. Epub 2010 Feb 1.
2
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.局限性原发性胃肠道间质瘤完全手术切除后无复发生存的预后列线图的开发与验证：一项回顾性分析
Lancet Oncol. 2009 Nov;10(11):1045-52. doi: 10.1016/S1470-2045(09)70242-6. Epub 2009 Sep 28.
3
DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.DOG1抗体在胃肠道间质瘤鉴别诊断中的应用：1840例病例研究
Am J Surg Pathol. 2009 Sep;33(9):1401-8. doi: 10.1097/PAS.0b013e3181a90e1a.
4
V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.V600E BRAF突变是KIT/PDGFRA野生型胃肠道间质瘤亚组中的替代性早期分子事件。
J Clin Pathol. 2009 Jul;62(7):613-6. doi: 10.1136/jcp.2009.064550.
5
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.尼洛替尼用于治疗对伊马替尼和舒尼替尼均耐药的晚期胃肠道间质瘤。
Eur J Cancer. 2009 Sep;45(13):2293-7. doi: 10.1016/j.ejca.2009.04.030. Epub 2009 May 19.
6
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.伊马替尼的血浆水平与不可切除/转移性胃肠道间质瘤患者的临床获益相关。
J Clin Oncol. 2009 Jul 1;27(19):3141-7. doi: 10.1200/JCO.2008.20.4818. Epub 2009 May 18.
7
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.局部原发性胃肠间质瘤切除术后辅助使用甲磺酸伊马替尼：一项随机、双盲、安慰剂对照试验。
Lancet. 2009 Mar 28;373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6. Epub 2009 Mar 18.
8
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.初治及伊马替尼耐药胃肠道间质瘤中的新型V600E BRAF突变
Genes Chromosomes Cancer. 2008 Oct;47(10):853-9. doi: 10.1002/gcc.20589.
9
Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.胃肠道间质瘤：形态学、分子病理学、预后及鉴别诊断综述
Arch Pathol Lab Med. 2006 Oct;130(10):1466-78. doi: 10.5858/2006-130-1466-GSTROM.
10
Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.胃肠道间质瘤的恶性程度评估及预后：综述
Hum Pathol. 2002 May;33(5):478-83. doi: 10.1053/hupa.2002.124123.
Zotero 插件